Google
BIOCQ 株価分析 — Biocept Inc. (Healthcare >> Diagnostics & Research)
BIOCQ に関するよくある質問
BIOCQのROE（自己資本利益率）は？
Biocept Inc.のROEは-13,593.79%です。
BIOCQの配当利回りは？
Biocept Inc.の配当利回りは0.00%です。
BIOCQの品質スコア（Quality Score）は？
当社のAIはBIOCQの総合財務品質を100点中38点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
BIOCQは今が買い時ですか？
当社AIのタイミングスコアは100点中0点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
BIOCQはどのセクターに属しますか？
Biocept Inc.はHealthcare >> Diagnostics & Researchセクターに分類されます（NASDAQ市場）
BIOCQ AI Analysis Summary
Our AI summary for BIOCQ: Biocept Inc. (NASDAQ), Healthcare >> Diagnostics & Research sector. The stock currently trades at a P/E of 0.00, ROE of -13,593.79%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 0/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.00
Price
0
(0%)
Day Change
|
|
|---|
BIOCQ, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
44% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | N/A |
| PBV / Sector |
N/A / -29.69
|
| Earning Per Share | -15.05 |
| PE / Sector |
N/A / 48.18
|
| PEG or PE/Growth / Sector |
N/A / 1.64
|
| Average 1M Daily Value |
0.273960000000
GREAT
|
| Average 1W Daily Value |
0.478800000000
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
39% |
| ポイントになる統計 |
|
68% |
| 配当 |
|
8% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:33 |
| Symbol | BIOCQ |
| Name | BIOCEPT INC. |
| Sector | Healthcare >> Diagnostics & Research |
| Market | NASDAQ |
| Listed Shares | 2.63 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | N/A / 38,081.42 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 9955 Mesa Rim Road, San Diego, CA, United States, 92121
Phone: 858 320 8200
Website: https://biocept.com
Description: Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California. On October 13, 2023, Biocept, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Diagnostics & Research
Click a bubble to view stock details · Bubble size represents market capitalization share
